NCT02053376View on ClinicalTrials.gov

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 7, 2018

Study Completion Date

May 14, 2018

Conditions
Metastatic Biliary Tract Carcinoma
Interventions
DRUG

Regorafenib

regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Nathan Bahary, MD

OTHER

NCT02053376 - A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | Biotech Hunter | Biotech Hunter